Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Musial, J.
Right arrow Articles by Celinska-Lowenhoff, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Musial, J.
Right arrow Articles by Celinska-Lowenhoff, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 1566-1568
© 2003 British Society for Rheumatology

Letter to the Editor

Polymyositis associated with infliximab treatment for rheumatoid arthritis

J. Musial, A. Undas and M. Celinska-Lowenhoff

Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland

Correspondence to: J. Musial, Department of Medicine, Jagiellonian University, Skawinska 8, PL-31-066 Krakow, Poland. E-mail: mmmusia@cyf-kr.edu.pl

The first 10% of the full text of this article appears below.

SIR, Treatment of rheumatoid arthritis (RA) with the chimeric anti-tumour necrosis factor {alpha} (TNF-{alpha}) monoclonal antibody infliximab has been proven efficacious and well tolerated [1, 2]. However, there are concerns about the safety of such treatment, with reports about induction of autoimmune phenomena [anti-double-stranded DNA (dsDNA) antibodies] and, rarely, development of systemic lupus erythematosus [3–5]. We describe a patient with RA who developed polymyositis following treatment with infliximab.

A 52-yr-old woman presented in January 2001 with . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
P. Riley, L. J. McCann, S. M. Maillard, P. Woo, K. J. Murray, and C. A. Pilkington
Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis
Rheumatology, June 1, 2008; 47(6): 877 - 880.
[Abstract] [Full Text] [PDF]